HealthPolitics

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 01:52:23 UTC.

Briefings

A Democratic landslide victory in the midterm elections may empower Senator Bernie Sanders to influence the FDA's funding bill, as he leads the Senate health committee. The Prescription User Fee Drug Act must be renewed before September 30, 2026, to prevent disruptions to FDA medicine approvals. Sanders opposes the core premise of the user fee structure, which collects fees from pharmaceutical companies to fund agency reviews.

Key points

• Sen. Bernie Sanders (I-Vt.) leads the Senate health committee and opposes the core premise of the Prescription User Fee Drug Act.
• The current law expires on September 30, 2026, and renewal is required to maintain FDA's ability to approve medicines.

Context

The FDA collects user fees from pharmaceutical companies to fund its reviews of medicines. Democrats' landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration, in part by empowering a major critic of the program.

Limitations

Evidence is limited to the provided text, which does not specify the exact nature of the midterm election outcome or the specific details of the upcoming negotiations. The article does not provide additional background on the political context or the specific impact of the renewal deadline.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 06:54:03 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidield5qa2otgqz2syysgrkobfiy77jcaqojc53kmy3zdsxtosolm